Indication

For treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy

Medicine details

Medicine name:
tofacitinib (Xeljenz)
SMC ID:
SMC2463
Pharmaceutical company
Pfizer Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Publication due date:
12 September 2022
SMC meeting date:
TBC
Patient group submission deadline:
04 July 2022